Find information on Colorectal Cancer Screening CRC Screening and Colon Cancer Screening including clinical documentation requirements and medical coding guidelines. Learn about the importance of early detection and prevention of colorectal cancer. This resource provides healthcare professionals with the necessary information for accurate and efficient documentation and coding related to C Colorectal Cancer Screening.
Also known as
Encounter for screening for colorectal cancer
Screening for colorectal cancer using fecal occult blood test, sigmoidoscopy, or colonoscopy.
Encounter for screening for malignant neoplasms
General screening for various malignant neoplasms, including colorectal cancer.
Malignant neoplasm of colon, rectum, rectosigmoid junction, and anus
Diagnosis codes for colorectal cancer, used for diagnosed cases, not screening.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is screening for colorectal cancer?
Yes
Personal history of colorectal cancer?
No
Do not code for colorectal cancer screening. Code the presenting diagnosis.
When to use each related code
| Description |
|---|
| Screening for colorectal cancer in average-risk adults. |
| Evaluation of signs/symptoms suggesting colorectal cancer. |
| Surveillance after prior colorectal cancer diagnosis or polyp removal. |
Documentation lacks specificity regarding the type of CRC screening performed (e.g., colonoscopy, FIT) impacting code selection (e.g., G0105, G0121, G0389).
Insufficient documentation of personal/family history of CRC or polyps, affecting risk assessment and appropriate code assignment (e.g., Z12.11, Z80.0).
Vague documentation of findings (e.g., polyps) without size, location, or histology, hindering accurate coding for diagnostic colonoscopies (e.g., 45380, 45385).
Q: What are the most effective colorectal cancer screening strategies for average-risk patients based on current USPSTF guidelines and considering patient preferences?
A: The USPSTF recommends colorectal cancer screening for all adults aged 45 to 75 years. Several effective strategies exist, catering to patient preferences and resource availability. These include direct visualization tests like colonoscopy and flexible sigmoidoscopy, and stool-based tests such as high-sensitivity guaiac fecal occult blood tests (HSgFOBT), fecal immunochemical tests (FIT), and multi-target stool DNA tests (mt-sDNA). Colonoscopy remains the gold standard, allowing for both detection and removal of precancerous polyps, but requires bowel preparation and carries a slightly higher risk of complications. Stool-based tests are less invasive but require more frequent testing intervals and may necessitate colonoscopy for follow-up if positive. Shared decision-making, considering patient preferences, comorbidities, and access to resources, is crucial for maximizing adherence and effectiveness. Explore how integrating patient-reported outcomes can enhance colorectal cancer screening program success.
Q: How can I improve colorectal cancer screening adherence rates in my practice, particularly among underserved populations facing barriers to care?
A: Improving colorectal cancer screening adherence, especially in underserved populations, demands a multi-pronged approach. Strategies include implementing patient navigation programs to guide individuals through the screening process, addressing language and cultural barriers, offering flexible screening options like at-home FIT tests, leveraging telehealth for education and follow-up, and reducing cost barriers through insurance coverage advocacy or exploring community-based resources. Furthermore, culturally sensitive educational materials and community outreach initiatives can promote awareness and address misconceptions about screening. Consider implementing a comprehensive program incorporating these elements to enhance adherence and reduce disparities in colorectal cancer outcomes. Learn more about culturally competent healthcare practices to enhance your outreach effectiveness.
Patient presents for colorectal cancer screening. Discussion regarding colorectal cancer risk factors including age, family history of colon cancer or polyps, personal history of polyps or inflammatory bowel disease (IBD such as ulcerative colitis or Crohn's disease), and lifestyle factors such as diet, smoking, and physical activity was conducted. Patient's average risk status was reviewed, and options for colon cancer screening including colonoscopy, fecal immunochemical test (FIT), fecal occult blood test (FOBT), Cologuard, and CT colonography (virtual colonoscopy) were explained. Benefits, limitations, and preparation required for each screening modality were discussed. Patient's preference for [Specific screening test chosen] was documented. The importance of early detection of colorectal cancer and precancerous polyps was emphasized. Patient education provided regarding bowel preparation, procedure scheduling, and follow-up. ICD-10 code Z12.1 (encounter for screening for malignant neoplasm of colon) is applicable. CPT code will be determined based on the chosen screening test (e.g., 45378 for colonoscopy, 82270 for FIT, G0105 for Cologuard). Recommendations for follow-up colonoscopy if indicated will be provided based on screening test results.